Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

NurExone Biologic Enters 5-Year Manufacturing Partnership with Made Scientific for Bone-Marrow-Derived Exosomes.

Aug 22, 2026•about 4 hours ago

Contract Type

partnership

HaifaBiotechnology

Description

NurExone Biologic has signed a binding letter of intent with Made Scientific for the exclusive manufacturing and aseptic filling of bone-marrow-derived exosomes. This partnership will consolidate their GMP manufacturing strategy and is set to produce its first batches by mid-2027.

Company Information

Company

NurExone Biologic

Location

MINUS 1 ENTRY, GROUND FLOOR OF BLDG B

Haifa, Haifa District, Israel

About

NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.

Related People

Suggested for you
Lior
Likely contact at this company
••••••••@••••••••

See Lior's verified email →

Limor
Senior decision-maker at this company
••••••••@••••••••

See Limor's verified email →

Predictive Intelligence
Strategic

ML-powered predictions for NurExone Biologic's next move

Learn about Strategic plan

Agreement Insights

Based on industry data
Strategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months

NurExone Biologic signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.